TrialESMO open2023

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

E de Azambuja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.